Laurus Labs Limited (LAURUSLABS) reports a 23% revenue increase for FY26, with EBITDA margin at 26.8%.
Laurus Labs Limited (NSE: LAURUSLABS) stock price moves up 5% intraday to ₹1683.0, testing resistance in the Healthcare sector.
Laurus Labs Limited (NSE: LAURUSLABS) announces Q1 FY27 results with 29% revenue growth, ₹644 Cr EBITDA, and 31.8% EBITDA margins.